PD patients with GBA mutations, compared with those without mutations, have been reported to present a characteristic biological and clinical phenotype with reference to aggregation of α-Syn, impaired lipid metabolism, cognitive dysfunction, disease progression, and survival time, indicating a definite effect of GBA mutations on the prognosis of PD [16,17,18,19,20,21,22]. This evidence concerns the gene GBA1 and Parkinson disease.